Videos

Andrew Zelenetz, MD, offers guidance on how PI3Ki (phosphoinositide 3-kinase inhibitors) fit into the treatment landscape of chronic lymphocytic leukemia.

Andrew Zelenetz, MD, offers tips for management of idelalisib-associated diarrhea during treatment for chronic lymphocytic leukemia.

Review of a phase III trial of idelalisib + rituximab in previously treated patients with chronic lymphocytic leukemia (CLL).

Patient is switched for treatment of chronic lymphocytic leukemia from ibrutinib to idelalisib + rituximab due to development of atrial fibrillation.

A key opinion leader highlights alternative treatment options to ibrutinib in the first-line setting for chronic lymphocytic leukemia.

Andrew Zelenetz, MD, outlines the case of a 77-year-old man with chronic lymphocytic leukemia.

Mehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.

Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab combined with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.

The progression of disease in MPNs and how genetic testing may inform therapy.

A discussion of the role of the JAK2 mutation and other factors in the development of MPNs.

Dr Verstovsek and Dr Kuykendall discuss the limitations of past treatments for MPNs.

Experts discuss the differences between essential thrombocythemia [ET], polycythemia vera [PV], and myelofibrosis [MF] and refinement of diagnosis.

Chevon Rariy, MD, discusses how the coronavirus disease 2019 pandemic has impacted the adoption of telehealth and the creation of the in-home infusion program, which allows cancer patients to continue their treatment at home while quarantining.

Eleni Gkika, MD, a radiation oncologist at the University Medical Center Freiburg, discusses the future of treatment for patients with advanced hepatocellular carcinoma.

Risa Wong, MD, reviews the standard treatment options for patients with metastatic urothelial cancer.

Marie E. Cabanillas, MD, discusses current unmet needs in advanced or metastatic TRK fusion-positive thyroid cancer.

David M. O’Malley, MD, discusses the prognosis and historical treatment options for patients with platinum-agnostic ovarian cancer.

Bijal Shah, MD, MS, discusses the timing of treatment with chimeric antigen receptor T-cell therapy in regard to the data from the ZUMA-3 trial of brexucabtagne autoleucel in patients with acute lymphoblastic leukemia.

Brian I. Rini, MD, discusses the benefits of long-term follow-up for trials and the results from 42-month follow-up of the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line therapy for patients with advanced clear cell renal cell carcinoma.

Dr Andrew J. Armstrong reviews the safety of LuPSMA therapy as compared to cabazitaxel as seen in the phase 2 TheraP trial and comments on sequencing strategies for patients with metastatic castration-resistant prostate cancer.

An expert in prostate cancer comments on the appropriate patient population for Lutetium-177 PSMA-617 therapy for the management of metastatic castration-resistant prostate cancer.

Dr Andrew J. Armstrong reviews the phase 3 VISION trial evaluating the use of LuPSMA therapy in patients with progressive PSMA-positive metastatic castrate-resistant prostate cancer.

Lara Traeger, PhD, discusses recommendations from the American Society of Clinical Oncology for coping with moral distress and burnout.

Susan Ash-Lee, discusses compassionate care in oncology and an ongoing series of resources, provided by the organization for providers.

Michael J. Overman, MD, discusses the advances in testing for rare genomic alterations in colorectal cancer.

Scott Kopetz, MD, PhD, FACP, reviews the results of the phase 1b multicenter KISIMA-01 study, for which he presented preliminary results during the ESMO World Congress of Gastrointestinal Cancer 2021.

Paul Barr, MD, discusses the results of the RESONATE-2, which evaluates efficacy of the Bruton’s tyrosine kinase inhibitor, ibrutinib versus chlorambucil in patients who are 65 years old or older with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Peter Martin, MD, provides his expert opinion on how to close the gap between recommended treatment pattens for mantle cell lymphoma and patterns observed in the real-world setting.

Maurie Markman, MD, addresses different treatment options, including checkpoint inhibitors, for patients with endometrial cancer.

Andrew J. Armstrong, MD, MSc, discusses the survival benefit of LuPSMA therapy in patients with metastatic castration-resistant prostate cancer and evaluates the response to therapy compared with other agents.